Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies

Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies

February 05, 2007

Wyeth - World's Fourth Largest Biopharmaceutical Company -
Builds on Commitment to Innovation in Hemophilia


    MADISON, N.J., Feb. 5 /Xinhua-PRNewswire/ -- Wyeth
Pharmaceuticals, a division of Wyeth (NYSE: WYE), and
Nautilus Biotech in Evry, France, today announced the
signing of a research collaboration and license agreement
to discover and develop novel recombinant Factor IX
proteins for the treatment of hemophilia B. These extended
half-life proteins will be designed to enhance patient
convenience as they will reduce the number and frequency of
treatments needed. 
 
    As part of the agreement, Nautilus Biotech will apply
its proprietary technology to improve the duration of
action of recombinant hemophilia B therapy.  The Nautilus
Biotech technology makes minimal and specific changes to
amino acids sequences in order to slow the breakdown of the
protein in the body.

    "Wyeth is continually evaluating technologies for
next-generation hemophilia products that provide unique and
improved features for patients.  This research partnership
enhances Wyeth's presence in biopharmaceuticals and builds
upon our history of innovation in hemophilia
research," says Cavan Redmond, Executive Vice
President and General Manager, BioPharma Business Unit at
Wyeth Pharmaceuticals.
 
    Under the terms of this agreement, Wyeth will develop,
manufacture and market products derived from the
collaborative research.  Nautilus Biotech will receive an
upfront payment, research and development fees, milestone
payments from Wyeth associated with development, regulatory
filings and approvals, and royalty payments based on net
sales of products.  

    "Wyeth has an impressive track record as a pioneer
in developing state-of-the-art hemophilia therapies and
Nautilus Biotech has a unique technology for improving
protein medicines. We believe that the collaboration
between Wyeth and Nautilus will offer exciting new
therapeutic approaches for hemophilia," says Manuel
Vega, Chief Executive Officer of Nautilus Biotech. 

    Hemophilia is a rare, inherited blood-clotting disorder
that affects approximately 130,000 people worldwide.  People
with hemophilia are deficient in one of the key proteins --
either Factor VIII (hemophilia A) or Factor IX (hemophilia
B) -- that are vital in the clotting cascade to prevent
bleeding.  Both forms of hemophilia are characterized by
spontaneous hemorrhages or prolonged bleeding, typically
into joints and soft tissue.  Patients with hemophilia A or
hemophilia B are dependent on protein replacement therapy
with Factor VIII or Factor IX, respectively, for life.  

    Wyeth Pharmaceuticals, a division of Wyeth, has leading
products in the areas of women's health care, cardiovascular
disease, central nervous system, inflammation,
transplantation, hemophilia, oncology, vaccines and
nutritional products. Wyeth is one of the world's largest
research-driven pharmaceutical and health care products
companies. It is a leader in the discovery, development,
manufacturing and marketing of pharmaceuticals, vaccines,
biotechnology products and non-prescription medicines that
improve the quality of life for people worldwide. The
Company's major divisions include Wyeth Pharmaceuticals,
Wyeth Consumer Healthcare and Fort Dodge Animal Health.

    The statements in this press release that are not
historical facts are forward-looking statements based on
current expectations of future events and are subject to
risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such
statements.  These risks and uncertainties include risks
associated with the inherent uncertainty of the timing and
success of product research, development and
commercialization (including with respect to our pipeline
products), drug pricing and payment for our products by
government and third-party payors, manufacturing, data
generated on the safety and efficacy of our products,
economic conditions including interest and currency
exchange rate fluctuations, changes in generally accepted
accounting principles, the impact of competitive or generic
products, trade buying patterns, global business operations,
product liability and other types of litigation, the impact
of legislation and regulatory compliance, intellectual
property rights, strategic relationships with third
parties, environmental liabilities, and other risks and
uncertainties, including those detailed from time to time
in our periodic reports filed with the Securities and
Exchange Commission, including our current reports on Form
8-K, quarterly reports on Form 10-Q and annual report on
Form 10-K, particularly the discussion under the caption
"ITEM 1A, RISK FACTORS." We assume no obligation
to publicly update any forward-looking statements, whether
as a result of new information, future developments or
otherwise.   


    For more information, please contact:

    Media: 

     Gerald Burr
     Wyeth Pharmaceuticals
     Tel:  [phone]

     Candace Steele
     Wyeth Pharmaceuticals
     Tel:  [phone]

    Investor: 

     Justin Victoria, Wyeth
     Tel:  [phone] 


SOURCE  Wyeth Pharmaceuticals